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Abstract 
Background 
Statins are commonly prescribed worldwide and recent evidence suggests they may increase the risk 
of herpes zoster. 
Objective 
 To quantify the effect of statin exposure on the risk of zoster in the UK. 
Methods 
A matched case-control study was conducted using data from UK primary care and hospital records. 
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Patients >18 years with an incident diagnosis of zoster were matched to up to four controls on age, 
sex and general practice. Exposures were: ever use of a statin; daily dosage of most recent statin 
prescription; time since most recent statin prescription. The primary outcome was an incident 
diagnosis of zoster. Odds ratios were estimated from conditional logistic regression and adjusted for 
potential confounders.  
Results 
A total of 144,959 incident cases of zoster were matched to 549,336 controls. Adjusted analysis 
suggested strong evidence for an increase in risk of zoster related to statin exposure (OR:1.13, 95% 
CI:1.11,1.15). There was also an increasing risk with increasing dose in current and recent users (p-
trend<0.001), and an attenuation of excess risk in previous users as time since last exposure 
increased (p-trend<0.001).  
Conclusion 
These findings are consistent with the hypothesis that statin therapy leads to an increase in the risk 
of zoster.  
 
Introduction  
Herpes zoster (commonly known as shingles) is caused by the reactivation of latent varicella zoster 
virus when specific cell mediated immunity becomes compromised. Zoster presents as a painful 
dermatomal vesicular rash. Healing occurs over a period of two to four weeks, and often results in 
scarring and permanent localised changes in skin pigmentation 1. The incidence of zoster is strongly 
associated with age, and 30% of cases occur in patients aged over 55 years 2. A range of conditions 
such as rheumatoid arthritis, imflammatory bowel disease, chronic obstructive pulmonary disorder, 
chronic kidney disease and depression are also associated with an increased risk of zoster 3. 
Postherpetic neuralgia develops (PHN) in 12% of zoster patients aged 50 years or over 1,4, and may 
be associated with intense pain that can last for years. A live zoster vaccine is available with efficacy 
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in reducing the risk of zoster and postherpetic neuralgia among immunocompetent patients over 50 
years old 5-7, although the vaccine is only routinely available in patients aged between 70 and 79 
years in the UK 8 and recommended for patients over 60 years in the USA.  
Statins are lipid lowering drugs that reduce the risk of cardiovascular disease in both primary and 
secondary care 9-12. In the 12 months preceding March 2008, 45.2 million statin prescriptions were 
dispensed in primary care in England making them the most commonly prescribed class of drugs in 
the UK  13. Along with being lipid lowering agents, it has been posited that statins may also modulate 
systemic immune responses 14. Antoniou et al 15 and Chen et al 16 recently reported a small but 
significantly increased risk of zoster among patients from Ontario (hazard ratio (HR): 1.13, 95% 
confidence interval (CI): 1.10-1.17)  and Taiwan (HR: 1.21, 95% CI: 1.13, 1.29) respectively.  Although 
the mechanisms by which statins may increase the risk of zoster are not established, it has been 
hypothesised that statins have immunomodulating properties, which operate by decreasing the 
synthesis of isoprenoid phosphates that are required for the activation of Ras-related GTPases 17, 
causing the impairment of T-cell activation and proliferation.   
 
As statins are widely prescribed worldwide, any adverse effects have potentially substantial public 
health implications. An increased risk of zoster would not only impact on the quality of life of 
affected patients, but could also add to the burden on health services, given the high cost of 
treatment for postherpetic neuralgia 18. Hence, this study aims to quantify the effect of exposure of 
statins on the risk of herpes zoster in the general population of the UK.  
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Methods 
A matched case-control study was conducted to quantify the effects of statin use on the risk of 
zoster in the UK general population. 
Data source 
The data source for this study was the UK Clinical Practice Research Datalink (CPRD), which is a 
primary case database from general practitioners who use the Vision IT system and who have agreed 
at the practice level to participate 19. CPRD contains anonymised primary care data from 
approximately 9% of the UK population and is broadly representative of patients’ and practices’ 
characteristics in the UK 20. 60% of patients in the CPRD have linked data available in the Hospital 
Episode Statistics (HES), which has recorded hospital attendances in England since 1997.    
Selection of cases 
Zoster patients were identified from CPRD and linked HES data. All patients in the study population 
were 18 years or over and were under follow-up at any time between 01 January 2000 and 31 
December 2011. Patients were classified as cases in the CPRD if they had a first ever zoster diagnosis 
recorded during the study period and at least 12 months of follow-up in CPRD prior to this first 
diagnosis of zoster; the 12 month restriction was intended to exclude past cases of zoster which 
were retrospectively recorded soon after registration at a general practice 21. In HES, incident zoster 
was identified according to ICD-10 (international classification of diseases, 10th revision) codes (B02, 
B02.0, B02.1, B02.31, B02.7, B02.8, B02.9, G53.0) that appeared in the primary diagnosis field and 
the index date was said to be the hospital admission date of the first episode. The earliest record of 
zoster was used if zoster was recorded in both HES and the CPRD for the same patient.  
Selection of controls 
Up to 4 control patients were selected for each zoster case by incidence density sampling, matched 
on GP practice, age (within 1 year) and sex, and without reference to statin exposure status.  
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Controls had to be registered with no history of zoster or PHN on the index date of their matched 
case, and have at least 12 months of prior follow-up in CPRD prior to this date. When incidence 
density sampling is used the odds ratio obtained from a case control study unbiasedly estimates the 
rate ratio in the study base.22 Matching on practice was done to minimise confounding due to 
differences in GP practice policies and procedures, and by factors associated with geographical area 
including socioeconomic status. The index date for the controls was set to that of their matched 
case. A control patient could also later be included as a case if they developed zoster after this date.  
Potential controls were assumed to be inactive with the practice and excluded if they had no contact 
with their GP practice at any time between six months before and 12 months after the index date. 
Exposure 
The primary exposures were ever exposure to a statin and time since last exposure to a statin. The 
most recent prescription of a statin before index date was initially identified and patients were then 
categorised into ever or never exposed to a statin.  
To calculate time since last exposure, the duration of the most recent prescription before the index 
date was calculated from the number of tablets prescribed, combined with daily dosing instructions. 
When number of tablets or dosing instructions were not provided, the median number of tablets 
prescribed and number of tablets to be taken each day were imputed. Thirty days was then added to 
the prescription end date as a grace period to indicate that a patient could still be taking the same 
pills during this time period due to an excess of medication. Current statin use was defined as having 
a prescription for which the calculated duration included the index date. The number of months 
since statin exposure was calculated for non-current users by calculating the time between the end 
of the latest prescription plus the thirty day grace period, and index date. Months since exposure 
was categorised into current, 0-12 months since exposure, 12-36 months since exposure and >36 
months since exposure. 
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As a secondary exposure, daily dosage of most recent statin prescription was stratified into one of 
three categories based on published estimates of expected reductions in LDL-cholesterol from 
baseline 11. These categories were low (atorvastatin <20 mg, rosuvastatin <10 mg, cerivastatin <0.3 
mg, simvastatin <80 mg, fluvastatin at all doses, pravastatin at all doses, lovastatin at all doses), 
medium (atorvastatin 20 to <80 mg, rosuvastatin 10 to <40 mg, simvastatin ≥ 80 mg, cerivastatin 0.3 
to 0.4 mg), and high (atorvastatin ≥ 80 mg, rosuvastatin ≥ 40 mg, cerivastatin ≥ 0.4 mg).  
As a further exposure, duration of continuous use was calculated by retrospectively accumulating 
each patient’s prescriptions until there was a gap between the date of prescription and the end of 
the previous prescription. The date of the earliest prescription was then compared to the end date 
of latest prescription for non-current statin users, and date of the earliest prescription was 
compared to the index date for current statin users. Cumulative length of most recent exposure was 
categorised into less than 12 months and greater than 12 months.     
Statistical analysis 
Primary analysis 
The characteristics of the study population were described by case-control status. Conditional 
logistic regression was then used for analysis, so all odds ratios accounted for the matched variables 
of age (within 1 year), sex, practice, and calendar time. Univariate odds ratios, with 95% confidence 
intervals, were firstly calculated to explore the association between the risk of zoster and primary 
exposures of ever exposed to a statin (ever or never exposed, regardless of timing), and time since 
last exposure (current, 0-12 months since exposure, 12-36 months since exposure and >36 months 
since last statin exposure). Multivariate analyses were then carried out including the following 
possible zoster risk factors:3 BMI category (underweight (<18.5), normal weight (18.5-24.9), 
overweight (≥25-29.9), obese (≥30)), smoking status, alcohol use, cardiovascular disease (CVD), HIV, 
lymphoma, leukaemia, myeloma, haematopoietic stem cell transplantation, other 
immunosuppressive therapy, other unspecified cellular immune deficiencies, oral corticosteroids, 
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rheumatoid arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disorder (COPD), 
asthma, chronic kidney disease (CKD), depression, cancer, and diabetes. Details of how these risk 
factors were defined are outlined in appendix 1. All odds ratios were calculated using the baseline 
group of patients that had never been exposed to statins. A complete case analysis was done, such 
that individuals with missing data for BMI, smoking or alcohol were excluded; this makes the 
assumption that missingness of these factors is unrelated to the outcome of zoster, conditional on 
covariates.23  
Secondary analysis 
Adjusted odds ratios, with 95% confidence intervals, were calculated to explore the association 
between risk of zoster and dosage of latest prescription (low, medium, high), stratified by time since 
last exposure. For this analysis, due to small numbers, patients in the 12-36 months and >36 months 
since last prescription groups were collated. The association between risk of zoster and duration of 
continuous use (0-12 months, >12 months), stratified by time since last exposure, was also explored.  
Effect modification 
A potentially effect modifying role of age at diagnosis (index) date was explored using the likelihood 
ratio test and by calculating stratum specific odds ratios in the multivariable model. For this analysis, 
age was treated as a binary variable, using a cut-off point of 70 years old with the rationale that 
these results might inform zoster vaccine policy, and the zoster vaccine is not routinely available for 
patients under the age of 70 in the UK.  
Sensitivity analyses 
To assess the presence of ascertainment bias, exposure to angiotensin-converting enzyme inhibitors 
(ACE inhibitors) was used as a negative control as they are prescribed with similar regularity and 
duration as statins and there is no known association between these drugs and zoster. To assess the 
possibility of exposure misclassification in primary analyses, we carried out an analysis where a 
patient was only classified as exposed to statins if they had been continuously prescribed statins for 
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at least three months. Furthermore, to assess the short term effects of statins on the risk of zoster, 
we further stratified the time since last exposure analysis to include ≤3m since a statin prescription 
(new categories: current, ≤3m since stopping statins, >3-12m since stopping statins, >12-36m since 
stopping statins, >36m since stopping statins). 
 
Results 
Descriptive analysis 
A total of 144 959 incident cases of zoster were identified. They were matched to 549 336 controls 
that were not diagnosed with zoster. Table 1 outlines the descriptive details of the cases and 
controls. 59.4% of cases and 61.0% of controls were female. 22.2% of cases and 20.2% controls had 
ever been prescribed a statin prior to index date. Overall, 14.2% and 16.1% of cases and controls 
respectively had at least one variable with missing data (either alcohol status, BMI category, smoking 
status, or a combination of all three variables).  
Ever exposed to a statin 
Univariate analysis accounting for the matched variables age, sex and GP practice presented strong 
evidence for an increase in risk of zoster associated with ever being exposed to a statin (OR = 1.20, 
95% CI, 1.18 to 1.22). This association was attenuated when fully adjusted for potential confounders 
(OR: 1.13, 95% CI: 1.11, 1.15), but there was still strong evidence to suggest a modest increase in risk 
of zoster associated with ever being exposed to a statin.  
Time since last exposure 
Table 2 and Figure 1 show unadjusted and adjusted odds ratios for the effect of statin use on the risk 
of developing zoster according to the timing of last exposure to statins. There was strong evidence of 
an attenuation of the increased risk of zoster associated with statin use as time since last 
prescription increased (test for trend: p<0.001).  
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Dose 
Table 3 and Figure 2 show unadjusted and adjusted odds ratios for the effect of the dose of the most 
recent statin prescription and the risk of zoster, stratified by time since last exposure. Among current 
statin users and recent statin users (those with a last prescription <12 months before index date), 
there was strong evidence for an increasing trend in risk of zoster as statin dose increased (test for 
trend: p<0.001 in both instances). Confidence intervals became very wide for individuals who 
stopped their statin therapy >12 months before the index date.  
Duration of continuous use 
Results from fully adjusted analyses for duration of continuous use, stratified by time since last 
exposure, showed no clear evidence that the length of statin prescription modified the effect of 
statins on the risk of zoster. Full results are shown in appendices 2 and 3.  
Effect Modification  
There was no evidence that age (treated as a binary variable indicating if a patients was over 70) 
modified the effect of statins on the risk of zoster (p=0.41, stratified results in appendix 4).  
Sensitivity Analyses 
Negative control 
When fully adjusted for all covariates, there was a evidence of a small increase in risk of zoster 
associated with ever being exposed to an ACE inhibitor in comparison to never being exposed (OR: 
1.03, 95% CI: 1.01, 1.05, Table 4).  
3 months of prescription exposure 
When the statin exposed patients were required to have at least 3 months of statin prescriptions 
before being categorised into exposure, there was still evidence to suggest that ever being exposed 
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to statins increased the risk of herpes zoster (OR: 1.12, 95% CI: 1.09, 1.14) when adjusted for all 
potential confounders. 
 Time since last exposure (short term effects) 
Appendix 5 shows unadjusted and adjusted odds ratios for the effect of statin use on the risk of 
developing zoster according to the timing of last exposure to statins, including a category estimating 
the risk in patients whose last exposure was ≤3m prior to index date. There continued to be strong 
evidence of an attenuation of the increased risk of zoster associated with statin use as time since last 
prescription increased (test for trend: p<0.001).  
 
Discussion 
In this large matched case-control study, statin exposure was associated with a modest increase in 
risk of herpes zoster (OR=1.13, 95% CI 1.11-1.15). A dose response relationship was observed and 
there was an attenuation of the excess risk over time among people who had stopped their statin 
therapy. These observations are consistent with a causal effect. An additional analysis was 
conducted using ACE inhibitors as a negative control exposure and we witnessed a small association, 
suggesting that a small proportion of the observed association between statins and zoster may be 
attributable to ascertainment bias or confounding by indication, but the effect size (OR=1.03) 
suggests that this is unlikely to explain all of the association for statins. 
 
Strengths and weaknesses 
All incident cases of zoster were identified in this large population-based dataset during the 11 year 
follow up period, hence this study was highly powered to detect small effect sizes between the use 
of statins and risk of zoster.  
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The study may be prone to misclassification of zoster as in UK primary care diagnosis of zoster is 
clinically based with no laboratory testing available. However, a validation study in the Netherlands 
found that over 90.8% of diagnosed cases in general practice had antibodies indicating recent zoster 
infection and suggesting that a clinical zoster diagnosis has a high positive predictive value 24.  
A complete case analysis was used, which relies on the assumption the probability of these data 
being missing is independent of zoster risk, conditional on covariates.23 Given that only 14.2 % of 
cases and 16.1% of controls had missing data in smoking status, alcohol usage, or BMI category, any 
violation of the assumption is unlikely to importantly affect the results. Furthermore, in unadjusted 
analyses, effect estimates restricted to patients with no missing data were similar to estimates for 
the full study population.  
There would be a risk of residual confounding by indication if the indication for statins also increases 
the risk of zoster. Statins are prescribed for both primary and secondary prevention of 
cardiovascular disease (CVD), which is not known to be an important risk factor for zoster. All 
multivariate models were adjusted for prior CVD, and this adjustment had little effect on the 
estimated effect of statins on zoster risk, suggesting minimal confounding. It was not possible to 
adjust directly for confounding by indication in primary prevention (i.e. a high risk of CVD, without 
an actual prior CVD diagnosis), though we did adjust for important drivers of high CVD risk including 
age, sex, BMI, smoking, diabetes, chronic kidney disease, cancer, and rheumatoid arthritis. However 
some residual confounding, for example by cholesterol level 25, cannot be ruled out. 
 
We were unable to reliably estimate the adherence to statins of the patients included in the study, 
and therefore to assess the association between adherence to statin therapy and the risk of 
developing zoster. This is because CPRD does not collect data on drug adherence, and there was 
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substantial missingness in the data needed to estimate prescription duration, making indirect 
estimation of adherence difficult.  
 
In our negative control analysis we observed some association between ACE inhibitors use and 
zoster risk. The effect size was substantially smaller than in our main analysis, and the “statistical 
significance” should not be over-emphasised given the very high statistical power available. 
Nevertheless, the analysis suggests that a small part of the estimated association for statins may 
have been driven by non-causal factors, and there are two likely contenders: ascertainment bias, 
and confounding by indication. Ascertainment bias would occur if patients receiving regular 
preventative medications, such as statins or ACE inhibitors, were more likely to have a zoster 
diagnosis recorded due to the greater amount of GP contact associated with using these 
medications. We believe ascertainment bias is likely to have limited impact since zoster frequently 
presents with a very painful rash. A survey regarding immunisation practices in the United States 
among people aged 60 and over found that 95% of those who knew they had zoster sought care 
from their GP, hence the majority of zoster patients consult their GP regardless of other GP contact. 
In the UK context where healthcare is free at the point of delivery, we would expect that almost all 
patients would attend for care if they develop zoster. Residual confounding by indication may be a 
more likely explanation. As discussed above, we adjusted for prior CVD and for important drivers of 
CVD, but given the limitations of the data, some residual confounding is possible, and would likely 
apply similarly to both the ACE inhibitors and statins analyses, since the two drug classes have 
related indications.  
We carried out two sensitivity analyses to assess potential biases within the analysis strategy. The 
first analysis consisted of requiring at least three months of statin prescriptions before defining a 
patient as being exposed. Imposing this restriction reduced the effect size, but not enough to change 
the final conclusions, which shows that the original criteria for exposure was adequate to avoid 
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exposure misclassification. We also further stratified the time since last exposure analysis to include 
a category assessing the risk in patients whose last exposure was ≤3m prior to the index date. We 
continued to witness attenuation of the risk as time since exposure increased, with a relatively 
higher risk in those with the most recent prescriptions.  
 
Comparisons to other studies 
Although Antoniou et al15 and Chen et al16 undertook similar studies in Ontario and Taiwan 
respectively, this is the first study of its type within a UK setting. The strength of the association 
between risk of zoster and statin use is consistent with that found by both previous studies (1.13 
(1.10, 1.17) & 1.21 (1.13, 1.29) respectively). However, neither of these studies attempted to explore 
the association between time since last statin and zoster infection. Our study found that zoster risk 
decreased as the time since last statin exposure increased, suggesting that the risk of zoster can be 
reduced if the patient stops statin therapy.  
In this study, a dose response relationship was found in current statin users and although Antoniou 
et al classified statin dosage in the same manner as this study, they found no dose response 
relationship. Their study was however restricted to patients over the age of 66, whereas this study 
included all zoster patients and matched controls over the age of 18. Chen et al reported a higher 
risk of zoster associated with all statins prescribed at high daily dosages in comparison to those 
prescribed at low daily dosages. They stated that high doses of statins are prescribed to patients 
with high cholesterol levels, and there is limited evidence suggesting that high cholesterol levels are 
associated with zoster 25, which could partly explain the association found between statins and 
zoster. 
Conclusion 
This study adds to the growing literature suggesting that statin therapy may lead to a modest 
increase in the risk of herpes zoster. It is clear that the preventive benefits of statin therapy are likely 
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to outweigh the limited increase in zoster risk in many cases. However, this evidence should be 
taken into account by GPs when prescribing statins to those at high risk of zoster. We would also 
suggest that there may be an extra motivation to maximise zoster vaccine uptake among eligible 
patients who are also receiving a statin  
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What’s already known about this topic? 
• Studies in both Canada and Taiwan have recently reported small a but significantly 
increased risk of zoster in users of statins 
•  As statins are one of the most widely prescribed drugs in the UK, with around 45 million 
prescriptions every year, any adverse effects will have substantial public health 
implications 
What does this study add? 
• In this large matched case-control study, statin exposure was associated with a modest 
increase in the risk of herpes zoster (OR=1.13, 95% CI 1.11-1.15) 
•  A dose response relationship was observed, and there was an attenuation of the excess 
risk over time among people who had stopped their statin therapy, which indicates that 
the increase in risk is consistent with a causal effect 
• These results suggest that there may be an extra motivation to maximise zoster vaccine 
uptake among eligible patients who are also receiving a statin   
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Table 1: Description of cases and controls. Values are numbers (percentages) unless 
otherwise stated 
 
Matching factors Cases (n=144 959) Control (n=549 336)
Ever prescribed a statin:  
  Yes   32 119 (22.2) 111 023 (20.2)
  No 112 840 (77.8) 438 313 (79.8)
Sex:  
  Male  58 888 (40.6) 214 064 (39.0)
  Female 86 071 (59.4) 335 272 (61.0)
Age:  
  18-29 10 849 (7.48) 38 761 (7.06)
  30-49 28 762 (19.84) 104 708 (19.06)
  50-59 27 833 (19.2) 105 157 (19.1)
  60-69 31 134 (21.5) 121 108 (22.0)
  70-79 28 025 (19.3) 110 097 (20.0)
  80-89 15 891 (11.0) 61 566 (11.2)
  > 90 2465 (1.7) 7939 (1.4)
Socioeconomic status (practice level)  
  1 28 938 (20.0) 109 663 (20.0)
  2 28 853 (19.9) 109 253 (19.9)
  3 29 811 (20.6) 112 888 (20.5)
  4 30 550 (21.1) 115 678 (21.1)
  5 26 807 (18.5) 101 854 (18.5)
Other Characteristics  
Mean (IQR) length of follow-up (in years) 8.6 (4.3-12.1) 8.6 (4.3-12.1)
BMI category:  
  Underweight 2776 (1.9) 10 549 (1.9)
  Normal weight 50 530 (34.9) 188 060 (34.2)
  Overweight 47 886 (33.0) 177 603 (32.3)
  Obese 29 581 (20.4) 109 440 (19.9)
  Missing 14 186 (9.8) 63 684 (11.6)
Smoking Status:  
  Non-smoker 54 751 (37.8) 208 436 (37.9)
  Current smoker 36 107 (24.9) 141 826 (25.8)
  Ex-smoker 52 353 (36.1) 186 373 (33.9)
  Missing 1784 (1.2) 12 701 (2.3)
Alcohol use:  
  Non-drinker 14 481 (10.0) 56 774 (10.3)
  Current drinker 103 113 (71.1) 383 976 (69.9)
  Ex-drinker 12 786 (8.8) 45 242 (8.2)
  Missing 14 579 (10.1) 63 344 (11.5)
Cardiovascular Disease 15 855 (10.94) 53 352 (9.71)
HIV 128 (0.09) 97 (0.02)
Lymphoma 444 (0.31) 386 (0.07)
Leukaemia 205 (0.14) 368 (0.07)
Myeloma 492 (0.34) 816 (0.15)
Hematopoietic stem cell transplantation 26 (0.02) 3 (0.00)
Other unspecified cellular immune 
deficiencies  
95 (0.07) 190 (0.03)
Other immunosuppressive therapy 2 164 (1.49) 3 822 (0.70)
Oral corticosteroids 502 (0.35) 1 058 (0.19)
Rheumatoid arthritis 3 111 (2.15) 8 029 (1.46)
Systemic lupus erythematosus 387 (0.27) 818 (0.15)
Inflammatory bowel disease 1 851 (1.28) 5 118 (0.93)
COPD  6 815 (4.70) 20 201 (3.68)
Asthma 10 243 (7.07) 31 865 (5.80)
Chronic kidney disease  8 724 (6.02) 29 437 (5.36)
Depression 6 830 (4.71) 22 052 (4.01)
Diabetes: 11 430 (7.88) 41 320 (7.52)
  Type 1 396 (0.27) 1 054 (0.19)
  Type 2 10 359 (7.15) 38 136 (6.94)
  Unknown  675 (0.47) 2 130 (0.39)
Missing data in any variable 20 598 (14.2) 88 233 (16.1)
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Table 2: Odds ratios for the association between both ever exposed to a statin time since last statin, and zoster 
 Odds ratio (95% CI)
Statin Use Model 1 Model 2 Model 3 
Never  1.00 1.00 1.00
Ever 1.20 (1.18, 1.22) 1.17 (1.15, 1.19) 1.13 (1.11, 1.15) 
    Current 1.21 (1.19, 1.23) 1.18 (1.15, 1.20) 1.14 (1.12, 1.17) 
    <12m since stopping statins 1.15 (1.11, 1.20) 1.12 (1.07, 1.17) 1.08 (1.04, 1.13) 
    12-36m since stopping statins 1.17 (1.11, 1.23) 1.15 (1.08, 1.21) 1.11 (1.05, 1.18) 
    36m+ since stopping statins 1.13 (1.06, 1.21) 1.09 (1.02, 1.17) 1.06 (0.99, 1.14) 
Model 1 - Unadjusted model 
Model 2 - Unadjusted model, restricted to patients that had no missing data in all descriptive variables 
Model 3 - Adjusted for BMI category, smoking status, alcohol use, CVD, HIV, lymphoma, leukaemia, 
myeloma, haematopoietic stem cell transplantation, other immunosuppressive therapy, other unspecified 
cellular immune deficiencies, oral corticosteroids, rheumatoid arthritis, systemic lupus erythematosus, COPD, 
asthma, CKD, depression, cancer, and diabetes 
 
 
 
Table 3: Odds ratios for the association between dose of last statin prescription and zoster, stratified by time since last 
exposure 
 Odds ratio (95% CI)
Statin Use Model 1 Model 2 Model 3 
Never  1.00 1.00 1.00
    Current  
            Low 1.20 (1.18, 1.23) 1.17 (1.14, 1.19) 1.14 (1.11, 1.16) 
            Medium 1.23 (1.19, 1.27) 1.20 (1.16, 1.24) 1.16 (1.12, 1.20) 
            High 1.40 (1.27, 1.54) 1.35 (1.22, 1.50) 1.27 (1.15, 1.41) 
    <12m since stopping statins  
            Low 1.14 (1.09, 1.20) 1.12 (1.07, 1.18) 1.08 (1.03, 1.14) 
            Medium 1.18 (1.06, 1.31) 1.12 (1.00, 1.25) 1.07 (0.96, 1.20) 
            High 1.49 (1.03, 2.16) 1.40 (0.94, 2.07) 1.35 (0.91, 2.01) 
    >12m since stopping statins  
            Low 1.15 (1.10, 1.21) 1.13 (1.07, 1.18) 1.09 (1.04, 1.15) 
            Medium 1.14 (1.00, 1.29) 1.12 (0.98, 1.28) 1.08 (0.95, 1.24) 
            High 0.93 (0.47, 1.85) 0.70 (0.33, 1.51) 0.66 (0.30, 1.44) 
Model 1 - Unadjusted model 
Model 2 - Unadjusted model, restricted to patients that had no missing data in all descriptive variables 
Model 3 - Adjusted for BMI category, smoking status, alcohol use, HIV, CVD, lymphoma, leukaemia, 
myeloma, haematopoietic stem cell transplantation, other immunosuppressive therapy, other unspecified 
cellular immune deficiencies, oral corticosteroids, rheumatoid arthritis, systemic lupus erythematosus, 
COPD, asthma, CKD, depression, cancer, and diabetes
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Table 4: Odds ratio for the association betwe
 
 
 
  
  
ACE Inhibitor use Model 1 
Never  1.00 
Ever 1.11 (1.1
Model 1 - Unadjusted model 
Model 2 - Unadjusted model, restricted to pat
variables 
Model 3 - Adjusted for BMI category, smoking
myeloma, haematopoietic stem cell transplan
unspecified cellular immune deficiencies, oral
erythematosus, COPD, asthma, CKD, depressio
ht. All rights reserved. 
en ever exposed to an ACE inhibitor and zoster 
 
 
 
 
 
 
 
 Odds ratio (95% CI)
Model 2 Model 3
1.00 1.00
0, 1.13) 1.09 (1.07, 1.04) 1.03 (1.01, 1.05) 
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